JPMorgan Chase & Co. Has $4.24 Million Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

JPMorgan Chase & Co. trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 3.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,140,911 shares of the company’s stock after selling 42,505 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.16% of ImmunityBio worth $4,244,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IBRX. Captrust Financial Advisors bought a new position in shares of ImmunityBio in the 3rd quarter valued at about $41,000. Virtu Financial LLC acquired a new position in ImmunityBio in the third quarter valued at approximately $51,000. Algert Global LLC bought a new position in ImmunityBio in the second quarter valued at approximately $86,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in ImmunityBio during the 2nd quarter worth $105,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio Stock Down 3.3 %

Shares of NASDAQ IBRX opened at $2.94 on Friday. ImmunityBio, Inc. has a twelve month low of $2.28 and a twelve month high of $10.53. The company’s fifty day moving average is $3.69 and its 200-day moving average is $4.23. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -3.20 and a beta of 0.86.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IBRX shares. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. BTIG Research began coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Thursday.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.